March 01, 2017
UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (September 3-5, 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).
The event is designed to increase partnerships, business opportunities and meet the needs of the entire region, which imports large quantities of ingredients, and relies on a network of distributors and advanced finished dose manufacturers – increasingly important as generics consumption rises.
The pharma market in the MENA (Middle East and North Africa) economies are a mixture of developed, high-income healthcare systems, coupled with high growth regions in North Africa. Total pharma sales are an impressive $32bn – Middle East countries account for $21.3bn (€19.2bn) and North Africa $10.7bn (€9.7bn) – with a compound annual growth rate of 7% predicted through to 2020. Collectively, with rapidly increasing pharma sales in many gentrifying African nations, along with high per capita spends and universal healthcare in Middle East countries the region offers a robust opportunity for pharma expansion.
The event will attract leaders and key decision makers of the pharma industry from the Middle East and Africa, bringing the expertise and reach of the CPhI brand to the heart of this new pharma hub. Running alongside the exhibition, there will be content sessions on the latest trends, keynote addresses, and numerous networking opportunities. CPhI Middle East & Africa 2018 comes with the backing of regional government and pharma associations, and is expected to attract 200 local, regional and international exhibitors from 30 countries and 5,000 attendees.
Attendees at the event will be able to listen and partake in specialist sessions, with experts from solution providers, science and technology firms, consultants, government representatives and big pharma operating in the region. CPhI Middle East and Africa is especially tailored to optimize existing relationships and create new strategic alliances to ensure future business success.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.